The FDA approved EDTA for its metal-binding ability but has since issued the following warning: “The two EDTA drugs have established names that are easily confused and both are referred to in clinical practice as "EDTA." This confusion has resulted in medication errors in which some patients have received the wrong drug, which has been fatal in some cases or caused serious adverse reactions in others. The error is especially dangerous when edetate disodium is erroneously given to a patient who is supposed to receive edetate calcium disodium.
The two EDTA drugs have different approved uses and significantly different effects. Risks are low when infusion protocols are followed.
- Gerber M. Thirty Years of Progress in Cardiovascular Health, Townsend Newsletter. Feb/Mar 2006
- BELKNAP EL. EDTA in the treatment of lead poisoning. Ind Med Surg. 1952 Jun;21(6):305–306.
- FDA - Drug Safety Information for Patient and Providers - 37k - 2009-06-03